Intelligence » Lymphoma » Last Week

Subscribe to get latest posts via email or subscribe to a RSS feed.

Roche lymphoma drug drives high remission rate, longer survival: study

Sunday, December 10, 2017 -- (Reuters) - An experimental Roche Holding AG drug, added to standard therapy, led to a far higher rate of remission and helped patients with an advanced, aggressive blood cancer live significantly longer than the standard treatment alone, according to data from a mid-stage trial released at a medical meeting on Sunday.

Gilead's new drug keeps 56 percent of lymphoma trial patients alive

Sunday, December 10, 2017 -- (Reuters) - More than half of trial patients with an advanced, aggressive form of blood cancer lived for at least a year after one-time treatment with Yescarta, a novel therapy sold by Gilead Sciences Inc, according to study results presented on Sunday.

Mayo Clinic study: Increasing physical activity decreases risk of death from lymphoma

Wednesday, December 13, 2017 -- An observational study by researchers at Mayo Clinic has found that increasing physical activity not only decreased the risk of death from all causes but also decreased the risk of death specifically from lymphoma.

AstraZeneca's&nbspCalquence; (acalabrutinib) Demonstrates Activity in Relapsed or Refractory Mantle Cell Lymphoma Trial

Sunday, December 10, 2017 -- (MENAFN Editorial) CAMBRIDGE, England-Sunday, December 10th 2017 ()-- AstraZeneca and Acerta Pharma, its haematology research and development centre of excellence, today present...

Daiichi Sankyo Presents Phase 1 Data for EZH1/2 Dual Inhibitor DS-3201 in Patients with Non-Hodgkin Lymphomas at the 59th Annual Meeting of the American Society of Hematology

Monday, December 11, 2017 -- (MENAFN Editorial) TOKYO and BASKING RIDGE, N.J. and MUNICH, Dec. 11, 2017 /PRNewswire/ -- Daiichi Sankyo Company, Limited (hereafter, Daiichi Sankyo) today announced that prelimin...

Acalabrutinib Yields Promising Response Rates in Relapsed/Refractory Mantle Cell Lymphoma

Saturday, December 09, 2017 -- The median time to response (TRR) was 1.9 months. The median duration of response (DoR) was not reached, though the 12-month DoR rate was 72% (95% CI, 62-80%).

[Articles] Acalabrutinib in relapsed or refractory mantle cell lymphoma (ACE-LY-004): a single-arm, multicentre, phase 2 trial

Monday, December 11, 2017 -- Acalabrutinib treatment provided a high rate of durable responses and a favourable safety profile in patients with relapsed or refractory mantle cell lymphoma. These findings suggest an important role for acalabrutinib in the treatment of this disease population.

Acalabrutinib Receives FDA Approval for Mantle Cell Lymphoma

Tuesday, December 12, 2017 -- The FDA has granted accelerated approval to acalabrutinib (Calquence®) for the treatment of adults with mantle cell lymphoma whose cancer has progressed after receiving at least one prior therapy.

ASH: A+AVD Beats ABVD for Advanced Hodgkin’s Lymphoma

Monday, December 11, 2017 -- Lower combined risk of progression, death, or noncomplete response with A+AVD

argenx to provide updates on Phase 1-2 clinical trials of ARGX-110 in Acute Myeloid Leukemia and Cutaneous T-Cell Lymphoma during American Society of Hematology Annual Meeting

Monday, December 11, 2017 -- Workshop to be held on Monday, December 11th at 12:00 pm EST December 11, 2017 Breda, the Netherlands / Ghent, Belgium - argenx (Euronext Nasdaq: ARGX) a clinical-stage biotechnology company developing a deep...

BeiGene Presents Preliminary Phase 1b Data on BTK Inhibitor Zanubrutinib BGB-3111 in Non-Hodgkins Lymphoma at the 59th American Society of Hematology Annual Meeting

Saturday, December 09, 2017 -- CAMBRIDGE, Mass. and BEIJING, China, Dec. 09, 2017 -- BeiGene, Ltd. (NASDAQ:BGNE), a commercial-stage biopharmaceutical company focused on developing and commercializing innovative molecularly targeted and...

Rhizen Pharmaceuticals SA receives FDA Fast Track Designation for RP6530 tenalisib a highly selective dual PI3K delta-gamma inhibitor for the treatment of patients with relapsed-refractory peripheral T-cell lymphoma PTCL

Saturday, December 09, 2017 -- La Chaux-de-Fonds, Switzerland, Dec. 09, 2017 -- Rhizen Pharmaceuticals S.A., today announced that the U.S. Food and Drug Administration (FDA) has granted Fast Track Designation for RP6530 (tenalisib), the Company’s...

Mid-infrared spectroscopy used to diagnose lymphoma and melanoma

Wednesday, December 13, 2017 -- A blood test using infrared spectroscopy can be used to diagnose two types of cancer...

Phase 2 data for Roche’s lymphoma ADC doesn’t disappoint

Monday, December 11, 2017 -- With breakthrough designation from the FDA and priority medicine status in the EU, expectations for Roche’s antibody-drug conjugate for non-Hodgkin lymphoma polatuzumab vedotin are running pretty high. Phase 2 data presented at ASH 2017 suggests that optimism could be justified.